RSV is a common respiratory virus that usually causes mild, cold-like symptoms but can also affect the lungs. Anyone can become infected by RSV, and almost all children get an RSV infection by the time they are 2 years old. While most children recover from an RSV infection in a week or two, RSV infection can be dangerous for infants and some young children, causing difficulty breathing, low oxygen levels, and dehydration. In the United States, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lungs) and pneumonia (infection of the lungs) in children younger than 1 year of age. Children who get sick from RSV may need to be hospitalized, and some might even die.
The American Academy of Pediatrics (AAP) recommends Nirsevimab RSV Preventive Antibody (brand name Beyfortus) to all infants aged <8 months born during or entering their first RSV season. The RSV season is typically October through March.
Please see the RSV Preventive Antibody Immunization Information Statement (CDC) for what you need to know about the RSV preventive antibody for infants.
The AAP also recommends Nirsevimab be given to children 8 months through 19 months of age who are at increased risk of severe RSV disease and entering their second RSV season.
Raleigh Pediatrics will offer nirsevimab to all eligible patients beginning September 16, 2024 through March 31, 2025.
Visit our immunizations page for more information